ID   CC-LP-1
AC   CVCL_0205
SY   CC-LP-I; CCLP-1; CCLP1
DR   BTO; BTO_0002933
DR   MCCL; MCC:0000094
DR   cancercelllines; CVCL_0205
DR   Cell_Model_Passport; SIDM01889
DR   Cosmic; 927189
DR   DepMap; ACH-001959
DR   TOKU-E; 4041
DR   Wikidata; Q54808710
RX   CelloPub=CLPUB00275;
RX   PubMed=1355757;
RX   PubMed=27231123;
RX   PubMed=31109923;
RX   PubMed=35640676;
RX   PubMed=39026794;
CC   Part of: Biliary tract cancer cell line atlas.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 180 hours (PubMed=1355757).
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Unspecified (DepMap=ACH-001959).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (DepMap=ACH-001959).
CC   Caution: Indicated to derive from a female patient in PubMed=1355757, but has a X,Y amelogenin STR marker.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): DepMap=ACH-001959
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 9,12
ST   D16S539: 9,13
ST   D18S51: 13,14
ST   D21S11: 29,33
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 11,13
ST   FGA: 22
ST   Penta D: 12,13
ST   Penta E: 12
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 23
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=1355757; DOI=10.1002/ijc.2910520217;
RA   Shimizu Y., Demetris A.J., Gollin S.M., Storto P.D., Bedford H.M.,
RA   Altarac S., Iwatsuki S., Herberman R.B., Whiteside T.L.;
RT   "Two new human cholangiocarcinoma cell lines and their cytogenetics
RT   and responses to growth factors, hormones, cytokines or immunologic
RT   effector cells.";
RL   Int. J. Cancer 52:252-260(1992).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H.,
RA   Bardeesy N.M.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=31109923; DOI=10.1158/2159-8290.CD-19-0182; PMCID=PMC6677584;
RA   Goyal L., Shi L., Liu L.Y., Fece de la Cruz F., Lennerz J.K.,
RA   Raghavan S., Leschiner I., Elagina L., Siravegna G., Ng R.W.S., Vu P.,
RA   Patra K.C., Saha S.K., Uppot R.N., Arellano R.S., Reyes S., Sagara T.,
RA   Otsuki S., Nadres B., Shahzade H.A., Dey-Guha I., Fetter I.J., Baiev I.,
RA   Van Seventer E.E., Murphy J.E., Ferrone C.R., Tanabe K.K., Deshpande V.,
RA   Harding J.J., Yaeger R.D., Kelley R.K., Bardelli A., Iafrate A.J.,
RA   Hahn W.C., Benes C.H., Ting D.T., Hirai H., Getz G., Juric D.,
RA   Zhu A.X.-X., Corcoran R.B., Bardeesy N.M.;
RT   "TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in
RT   patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 9:1064-1079(2019).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//
RX   PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448;
RA   Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L.,
RA   Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J.,
RA   Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L.,
RA   Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J.,
RA   Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E.,
RA   Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W.,
RA   Vazquez F., Getz G., Bardeesy N.M.;
RT   "Generation of a biliary tract cancer cell line atlas reveals
RT   molecular subtypes and therapeutic targets.";
RL   bioRxiv 2024:07.04.601970-07.04.601970(2024).
//